El Instituto de Salud Carlos III utiliza cookies propias y de terceros para el correcto funcionamiento y visualización del sitio web por parte del usuario, así como la recogida de estadísticas. Si continúa navegando, consideramos que acepta su uso. Para más información visite nuestra Política de Cookies.
Ver más información

We protect your health through science

Search Bar

Usa comillas para buscar una secuencia de palabras exacta. Ej: "Proyectos Financiados"

Investigación

Special Pathogens

Líneas de investigación

Content with Investigacion Hepatitis .

Hepatitis

  1. Diseño de métodos diagnósticos para el estudio de los virus de las hepatitis (VH) A, B, C, D, E: Diseñamos sistemas de PCR para su detección y caracterización.
  2. Evaluación de métodos diagnósticos de los VH. Colaboramos con empresas para estudios de sensibilidad y especificidad de equipos diagnósticos.
  3.  Estudios de Seroprevalencia de los virus de las hepatitis.
  4.  Epidemiología genómica de genomas completos de VHA, VHB, VHC, VHD y VHE en colaboración con el ECDC. Estudios de trazabilidad del VHE.
  5. Caracterización molecular de virus de las hepatitis mediante secuenciación masiva:               a) VHB: mutantes de escape HBsAg (prevalencia y efectos en la detección del HBsAg). Estudio de mutaciones en epítopos de estimulación inmune y mutaciones asociadas a evolución clínica desfavorable.
    1. b) VHC: resistencias a los antivirales de acción directa. Análisis molecular de subtipos poco frecuentes.
      c) Estudios filogenéticos del VHD.
       d) Análisis genómico del VHE.
       e) Investigación etiológica de hepatitis no filiadas mediante estudios de metagenómica.

Search Bar
Custom

Publicaciones destacadas

Category
Sort

Characterization of an enhanced antigenic change in the pandemic 2009 H1N1 influenza virus haemagglutinin

Garcia-Barreno B, Delgado T, Benito S, Casas I, Pozo F, Cuevas MT, et al. Characterization of an enhanced antigenic change in the pandemic 2009 H1N1 influenza virus haemagglutinin. J Gen Virol. 2014;95(Pt 5):1033-42.

PUBMED DOI

Epidemic history of hepatitis C virus genotypes and subtypes in Portugal.

Palladino C, Ezeonwumelu IJ, Marcelino R, Briz V, Moranguinho I, Serejo F, Velosa JF, Tato Marinho R, Borrego P, Taveira N. 2018. Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. Sci Rep. 2018; 8:12266. (A; FI= 4.12; Q1 Multidisciplinary Sciences; DOI:10.1038/s41598-018-30528-0).

PUBMED DOI

Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study.

Palladino C, Sanchez-Carrillo M, Mate-Cano I, Vazquez-Morón S, Jiménez-Sousa MA, Gutiérrez-Rivas M, Resino S, Briz V. Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study. Sci Rep. 2017; 7(1):2892. (A; FI= 4.12; Q1 Multidisciplinary Sciences).

PUBMED DOI

Plasma miRNA profile at COVID-19 onset predicts severity status and mortality.

Fernández-Pato A; Virseda-Berdices A, Ryan P; Martínez-González O, Peréz-García F, Resino S, Martin-Vicente M, Valle-Millares D, Brochado-Kith O; Blancas R; Ceballos FC; Bartolome-Sánchez S; Vidal-Alcántara EJ; Alonso-Menchén D, Blanca-López N; Ramirez Martinez-Acitores I, Rava M, Jiménez-Sousa MA (‡ *), Amanda Fernández-Rodríguez (‡ *). Plasma miRNA profile at COVID-19 onset predicts severity status and mortality. Emerg Microbes Infect 2022; 11(1):676-688 (A; FI= 19.57; D1, Infectious Diseases; JCR 2021).

PUBMED DOI

Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: a prospective study.

García-Broncano P, Medrano LM, Berenguer J, Brochado O, González-García J, Jiménez-Sousa MA, Quereda C, Sanz J, Téllez MJ, Díaz L, Jiménez JL, Muñoz-Fernández MA, Resino S (*). Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: a prospective study. J Infect 2020; 80(1):99-110. (A; FI= 6.07; Q1, Infectious Diseases; JCR 2020).

PUBMED DOI

Efficacy of DNA amplification in tissue biopsy samples to improve the detection of invasive fungal disease

Buitrago MJ, Aguado JM, Ballen A, Bernal-Martinez L, Prieto M, Garcia-Reyne A, Garcia-Rodriguez J, Rodriguez-Tudela JL, Cuenca-Estrella M. Efficacy of DNA amplification in tissue biopsy samples to improve the detection of invasive fungal disease. Clin Microbiol Infect. 2013 Jun;19(6):E271-7. doi: 10.1111/1469-0691.12110. Epub 2013 Mar 7. PMID: 23464751.

PUBMED DOI

Unintended HIV-1 Infection During Analytical Therapy Interruption

Ugarte A, Romero Y, Tricas A, Casado C, Lopez-Galindez C, Garcia F, Leal L. J Infect Dis. 2020 Apr 27,221(10):1740-1742.

PUBMED DOI

Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses

Beltran-Pavez C, Bontjer I, Gonzalez N, Pernas M, Merino-Mansilla A, Olvera A, Miro JM, Brander C, Alcami J, Sanders RW, Sanchez-Merino V, Yuste E. J Virol. 2022 Jan 12, 96(1): e0134321

PUBMED DOI

HIV-1 envelope glycoproteins isolated from Viremic Non-Progressor individuals are fully functional and cytopathic

Cabrera-Rodríguez R, Hebmann V, Marfil S, Pernas M, Marrero-Hernández S, Cabrera C, Urrea V, Casado C, Olivares I, Márquez-Arce D, Pérez-Yanes S, Estévez-Herrera J, Clotet B, Espert L, López-Galíndez C, Biard-Piechaczyk M, Valenzuela-Fernández A, Blanco J. Sci Rep. 2019 Apr 3,9(1):5544

PUBMED DOI

Viral Characteristics Associated with the Clinical Nonprogressor Phenotype Are Inherited by Viruses from a Cluster of HIV-1 Elite Controllers

Casado C, Marrero-Hernández S, Márquez-Arce D, Pernas M, Marfil S, Borràs-Grañana F, Olivares I, Cabrera-Rodríguez R, Valera MS, de Armas-Rillo L, Lemey P, Blanco J, Valenzuela-Fernández A, Lopez-Galíndez C. mBio. 2018 Apr 10,9(2): e02338-17

PUBMED DOI

Viral and Cellular Factors Leading to the Loss of CD4 Homeostasis in HIV-1 Viremic Nonprogressors.

Colomer-Lluch M, Kilpelainen A, Pernas M, Peña R, Ouchi D, Jimenez-Moyano E, Dalmau J, Casado C, López-Galíndez C, Clotet B, Martinez-Picado J, Prado JG. J Virol. 2022 Jan 12, 96(1): e0149921. doi: 10.1128/JVI.01499-21. Epub 2021 Oct 20.

PUBMED DOI

Human Immunodeficiency Virus Type 1 Two-Long Terminal Repeat Circles: A Subject for Debate

Olivares I, Pernas M, Casado C, López-Galindez C. AIDS Rev. 2016 Jan-Mar,18(1):23-31

PUBMED DOI

Improved antibody cross-neutralizing activity in HIV-1 dual double infected LTNP patients.

María Pernas, Concepción Casado, Victor Sanchez-Merino, Alberto Merino-Mansilla, Isabel Olivares, Eloisa Yuste, Cecilio Lopez-Galindez. (2015) PLoS One. Aug 10; 10 (8):e0134054

PUBMED DOI

Contribution of the HIV-1 Envelope Glycoprotein to AIDS Pathogenesis and Clinical Progression

Valenzuela-Fernández A, Cabrera-Rodríguez R, Casado C, Pérez-Yanes S, Pernas M, García-Luis J, Marfil S, Olivares I, Estévez-Herrera J, Trujillo-González R, Blanco J, Lopez-Galindez C. Biomedicines. 2022 Sep 2,10(9):2172.

PUBMED DOI

Prevalence of HIV-1 dual infection in LTNP-Elite Controllers

María Pernas, Concepción Casado, Virginia Sandonis, Carolina Arcones, Carmen Rodríguez , Ezequiel Ruiz-Mateos , Eva Ramírez de Arellano , Norma Rallón , Margarita Del Val , Eulalia Grau, Mariola López-Vazquez , Manuel Leal , Jorge del Romero , Cecilio López Galíndez . (2013). J.of AIDS. 64, 3, 225-231. IF 4.262

PUBMED DOI

A Genome-to-Genome Analysis of Associations between Human Genetic Variation, HIV-1 Sequence Diversity, and Retroviral Control.

Istvan Bartha Jonathan M Carlson, Chanson J Brumme, Paul J McLaren, Zabrina L Brumme, Mina John, David W Haas, Javier Martinez-Picado, Cecilio López Galíndez, Andri Rauch, Huldrych F Günthard, Enos Bernasconi, Pietro Vernazza, Thomas Klimkait, Sabine Yerly, Jennifer Listgarten, Nico Pfeifer, Zoltan Kutalik, Todd M Allen, Viktor Müller, P Richard Harrigan, David Heckerman, Amalio Telenti, and Jacques Fellay, for the HIV Genome-to-Genome Study and the Swiss HIV Cohort Study. (2013). Elife. 2013;2:e01123

PUBMED DOI

Characterizing the antiviral effect of an ATR inhibitor on human immunodeficiency virus type 1 replication

Docando F, Casado C, Pernas M, Mota-Biosca A, López-Galíndez C, Olivares I. Arch Virol. 2020 Mar, 165(3):683-690

PUBMED DOI

HIV-1 Dual Infected LTNP-EC Patients Developed an Unexpected Antibody Cross-Neutralizing Activity

Pernas M, Sanchez-Merino V, Casado C, Merino-Mansilla A, Olivares I, Yuste E, Lopez-Galindez C. PLoS One. 2015 Aug 10,10(8): e0134054

PUBMED DOI

Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection

Pernas M, Tarancón-Diez L, Rodríguez-Gallego E, Gómez J, Prado JG, Casado C, Dominguez-Molina B, Olivares I, Coiras M, León A, Rodriguez C, Benito JM, Rallón N, Plana M, Martinez-Madrid O, Dapena M, Iribarren JA, Del Romero J, García F, Alcamí J, Muñoz-Fernández M, Vidal F, Leal M, Lopez-Galindez C, Ruiz-Mateos E. J Virol. 2018 Feb 12,92(5): e01805-17

PUBMED DOI

Elite controllers and lessons learned for HIV-1 cure

Lopez-Galindez C, Pernas M, Casado C, Olivares I, Lorenzo-Redondo R. Curr Opin Virol. 2019 Oct, 38:31-36

PUBMED DOI

Content with Investigacion Hepatitis .

List of staff

Información adicional

1.- The study of non-gastrointestinal zoonoses, some of them transmitted by vectors and/or emerging, aims to: 

  • The development and validation of new diagnostic and genotyping techniques represent important scientific-technical support to the National Health System, acting as a reference laboratory. 
  • Research on the Molecular Epidemiology of Coxiella burnetii studies the circulating genotypes and their association with the different clinical presentations of Q fever. 
  • Discovery of new pathogens: especially relevant in the case of Francisella with the description of F. hispaniensis, as well as taxonomically unknown variants of Bartonella, Borrelia and Rickettsia, found in reservoirs, vectors and clinical samples. 
  • Surveillance in nature analyzes kinetics, transmission cycles and reservoirs. 

• Genotyping techniques allow traceability studies to be carried out in the case of natural outbreaks or intentional release. • Method accreditation: ISO15189 standard (clinical samples), ISO17025 (environmental). 

2.- The study of bacteria with potential use in bioterrorism through participation in European projects (Joint Actions: QUANDHIP, EMERGE, SHARP) allows us to respond appropriately to possible health alert situations. An important methodological development has been carried out for the detection of these agents and a Rapid Response System has been implemented.

Content with Investigacion Hepatitis .